Proceeds from the facility will provide working capital to support the company’s CD101 and CD201 programs which are in development to treat serious fungal and multi-drug resistant bacterial infections.
Led by Jeff Stein, Ph.D., president and CEO, Cidara is a clinical-stage biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections.
The company is currently advancing its novel echinocandin antifungal, CD101, through Phase 2 studies in two indications and developing CD201, its bispecific antimicrobial immunotherapy, for the treatment of multi-drug resistant bacterial infections.
– CD101 IV is a once-weekly therapy intended for the treatment and prevention of invasive fungal infections.
– CD101 topical is an agent being studied for the treatment and prevention of vulvovaginal candidiasis (VVC), a prevalent mucosal infection.
– CD201 is a drug candidate selected from Cidara’s novel Cloudbreak™ platform, an immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.